TCT-128 Disruptive Endovascular Technology with Multilayer Flow Modulator Stents (MFM) as a Therapeutic Option in the Management of Thoraco-abdominal Aortic Aneurysms. Early results from MFM Registry

Purpose: To investigate the feasibility of regional anesthesia for endovascular repair of abdominal aortic aneurysms (AAAs). Methods: Since February 1995, 21 patients (17 men and 4 women; median age 67 years, range 49 to 80) have been treated with endovascular technique for true infrarenal AAA using Mialhe Stentor bifurcated grafts. A single dose of spinal anesthesia combined with epidural anesthesia was used in all procedures. Electrocardiography and arterial blood pressure were monitored. Results: No cases of emboli, hematoma, or graft migration were seen, and there were no reoperations or conversions to open operation. Arterial blood pressure was stable at a satisfactory level from induction of anesthesia throughout the procedure, and there was no period of clinically significant hypotension during any implantation. One patient died on the second postoperative day from cardiac and renal insufficiency. Three endoleaks were observed during the procedure; one healed spontaneously within 5 weeks, and the other two were repaired by endovascular techniques after 1 and 4 months, respectively. During follow-up, one patient died at 6 months from pancreatic carcinoma. Conclusions: The application of regional anesthesia is feasible for endovascular treatment of AAA. The arterial blood pressure remained stable throughout the procedure, and all patients, with two exceptions, were mobilized on the first day and placed on a regular diet. Based on these early results, it appears that regional anesthesia is feasible, effective, and safe for endovascular AAA repair.

Download Full-text

Early results of endovascular aneurysm sealing with chimney grafts to treat juxtarenal and suprarenal abdominal aortic aneurysms

Journal of Vascular Surgery ◽

10.1016/j.jvs.2018.09.065 ◽

2019 ◽

Vol 70 (1) ◽

pp. 43-52 ◽

Cited By ~ 2

Author(s):

Katherine Stenson ◽

Benjamin Patterson ◽

Matthew Joe Grima ◽

Jorg de Bruin ◽

Peter Holt ◽

...

Keyword(s):

Abdominal Aortic Aneurysms ◽

Aortic Aneurysms ◽

Early Results ◽

Abdominal Aortic

Download Full-text

Early Results of the Bolton Treovance Endograft in the Treatment of Abdominal Aortic Aneurysms

Journal of Endovascular Therapy ◽

10.1177/1526602817713736 ◽

2017 ◽

Vol 24 (4) ◽

pp. 559-565 ◽

Cited By ~ 7

Author(s):

Efstratios Georgakarakos ◽

George Pitoulias ◽

Nikolaos Schoretsanitis ◽

Christos Argyriou ◽

Dimitrios M. Mavros ◽

...

Keyword(s):

Abdominal Aortic Aneurysms ◽

Aortic Aneurysms ◽

Early Results ◽

Abdominal Aortic

Download Full-text

Early experience shows rapid shrinking of abdominal aortic aneurysms after endovascular treatment with Anaconda® device

VASA ◽

10.1024/0301-1526.36.3.199 ◽

2007 ◽

Vol 36 (3) ◽

pp. 199-204 ◽

Cited By ~ 8

Author(s):

Stehr ◽

Schnitzbauer ◽

Steinbauer ◽

Töpel ◽

Pfister ◽

...

Keyword(s):

Endovascular Treatment ◽

Clinical Success ◽

Abdominal Aortic Aneurysms ◽

Aortic Aneurysms ◽

Infrarenal Aortic Aneurysm ◽

Early Results ◽

Abdominal Aortic ◽

Aneurysm Diameter ◽

Endovascular Device

Background: The Anaconda® prosthesis is a new endovascular device for abdominal aortic aneurysms repair. Aim of the study was to evaluate successful access to the arterial site, safety and efficacy of stent placement and fixation, assessment of endoleaks, patency of the graft due to twists, kinks or obstruction within the first 30 days after the procedure. Secondary objectives were the assessment of clinical success after 6 months due to graft patency and aneurysm exclusion without endoleak as well as the continuing clinical success without showing aneurysm expansion or any graft failure. Patients and methods: Between 2003 and 2006 a total of 14 patients with infrarenal aortic aneurysm (median diameter prior to endovascular treatment: 56.7 mm (range: 50 to 70 mm)) were treated with the Anaconda® endovascular device. 8 of these patients were treated in accordance to a prospective Phase II clinical study protocol (Anaconda ANA 004). 6 more patients received the same endovascular device after CE-certification. Results: Primary and secondary objectives were achieved in 12 of 14 patients after 6 months. In one patient insertion of the graft system was impossible due to kinking and circular calcification of the iliac arteries. Iliac access utilizing an alternative stent graft system (Cook, Zenith) was also unsuccessful. This patient underwent a conversion to open surgery and died. Another patient died 6 months after treatment unrelated to the procedure. A significant reduction of the median aneurysm diameter from 56.7 to 49.0 mm (range: 45 to 54 mm) was achieved after 6 months (p = 0.05). No endoleak was seen in the follow up. Conclusions: Early results show that he Anaconda® endovascular device for aneurysm repair is a safe and effective device for patients with suitable abdominal aortic aneurysms and proper distal access vessels which results in significant aneurysm diameter decrease and a low complication rate after 6 months of follow-up.

Download Full-text